A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWER
  • Sponsors Knopp Biosciences
  • Most Recent Events

    • 28 Apr 2017 Results assessing the associations between plasma neurofilament heavy chain (NF-H) levels and outcome measures of disease severity, progression, and survival in amyotrophic lateral sclerosis patients from EMPOWER study (n=663), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 07 Mar 2017 According to Knopp Biosciences media release, results from this study were published in the journal Blood Cells, Molecules and Diseases.
    • 07 Mar 2017 Results published in the Knopp Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top